Data as of May 24
| 0.00 / 0.00%|
The 11 analysts offering 12-month price forecasts for Genomic Health Inc have a median target of 37.00, with a high estimate of 43.00 and a low estimate of 18.00. The median estimate represents a 0.00% increase from the last price of 37.00.
The current consensus among 16 polled investment analysts is to Hold stock in Genomic Health Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.